Astellas Pharma - ALPMY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.42
▲ +0.08 (0.77%)

This chart shows the closing price for ALPMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astellas Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.42.

This chart shows the closing price for ALPMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Astellas Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/24/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
4/16/2023CitigroupUpgradeNeutral ➝ Buy
8/10/2022CitigroupDowngradeBuy ➝ Neutral
4/12/2022CitigroupInitiated CoverageBuy
2/23/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
6/29/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
5/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/23/2020Morgan StanleyInitiated CoverageOverweight
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
(Data available from 7/23/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/26/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
1/25/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
4/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Astellas Pharma logo
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $10.42
Low: $10.12
High: $10.51

50 Day Range

MA: $9.91
Low: $9.39
High: $10.64

52 Week Range

Now: $10.42
Low: $9.15
High: $15.90

Volume

124,441 shs

Average Volume

184,151 shs

Market Capitalization

$18.86 billion

P/E Ratio

148.86

Dividend Yield

2.93%

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Astellas Pharma?

The following sell-side analysts have issued stock ratings on Astellas Pharma in the last twelve months: Jefferies Financial Group Inc..
View the latest analyst ratings for ALPMY.

What is the current price target for Astellas Pharma?

0 Wall Street analysts have set twelve-month price targets for Astellas Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Astellas Pharma in the next year.
View the latest price targets for ALPMY.

What is the current consensus analyst rating for Astellas Pharma?

Astellas Pharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALPMY, but not buy more shares or sell existing shares.
View the latest ratings for ALPMY.

What other companies compete with Astellas Pharma?

How do I contact Astellas Pharma's investor relations team?

Astellas Pharma's physical mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company's listed phone number is (133) 244-3000. The official website for Astellas Pharma is www.astellas.com. Learn More about contacing Astellas Pharma investor relations.